Go to main content

As an easy-to-use and highly reliable inhalation powder, the antipsychotic ADASUVE® has revolutionized the treatment of agitation in patients suffering from schizophrenia or bipolar disorder. This was also confirmed by experts attending this year’s European Psychiatry Association (EPA) Congress Vienna. Speaking during the EPA satellite symposium on “Current management of psychiatric emergencies”, Dr. Rudolf Widmann, CEO of AOP Orphan, highlighted the fact that “since ADASUVE® was approved by the EMA in February 2013, 5,000 patients across Europe have been able to benefit from this non-invasive and safe option.” 

Just as quick and effective as an injection – but not invasive and therefore gentler
ADASUVE® is and oral inhalation product that combines the patented Staccato system with loxapine (a proven antipsychotic). In the Staccato system, pure loxapine is evaporated, turning it into an aerosol that is absorbed by the lungs and which subsequently enters the blood circulation. A single inhalation transports the entire drug into the lungs and the body’s circulation, bringing about a noticeable decrease in agitation within just ten minutes.

This non-invasive treatment option is preferred by patients over an injection, and thereby supports the therapeutic alliance between patient and physician in a safe and effective way in this critical situation. Dr. Widmann continued: “This is why we, as a company, are doing everything we can with our licensor, Ferrer, to be able to offer this innovative treatment option to a broader patient base.

ADASUVE® is available in doses of 9.1 mg and indicated to control cases of mild or moderate agitation in patients suffering from schizophrenia or bipolar I disorder. In view of the fact that agitation in these people represents an acute and intermittent state, it is to be assumed that treatment with ADASUVE® will only be on a sporadic basis. 

The Austrian pharmaceutical company AOP Orphan markets ADASUVE® in Austria, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland and Slovakia.

About AOP Orphan
AOP Orphan was one of the first companies to enter the sector of Rare Diseases in Europe and continues to be a trailblazer in the field of Orphan Diseases to this day. The Orphan Diseases specialist researches, produces and sells innovative solutions, concentrating on three treatment areas: hematology and oncology, cardiology and pulmonology, and neurology and psychiatry. AOP Orphan is active at an international level with an export ratio of 70% and is one of the leading players in the Orphan Drug market. www.aoporphan.com 

Further inquiries 

AOP Orphan Pharmaceuticals AG
Wilhelminenstraße 91/IIf
1160 Vienna
T +43 1 503 72 44-24
F +43 1 503 72 44-61